SuperworthAspire Biopharma PE ratio ASBP
Share price divided by earnings per share over the last twelve months, since 2023.
- Today, Oct 23, 2026
- n/m
- not a meaningful number
- Last meaningful
- 23.9×
- May 2024
- Peer median
- 10.1×
Aspire Biopharma's PE ratio is not a meaningful number today: diluted EPS for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.
It was last meaningful in May 2024, at 23.9×.
PE ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2024 | 23.9× | 23.1× | 25.5× |
| 2023 | 23.2× | 20.8× | 31.9× |
Against its peers
Companies in Drug Manufacturers - General nearest Aspire Biopharma's size, closest first, today.
| Company | PE ratio |
|---|---|
| ASBPAspire Biopharma | n/m |
| ATNMActinium Pharmaceuticals | 4.2× |
| SPROSpero Therapeutics | 10.1× |
| LFVNLifevantage | 14.7× |
| Peer median | 10.1× |
What the PE ratio tells you
Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.
Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.
More on Aspire Biopharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.